Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

Andreas Hochhaus,Tamas Masszi,F. Giles,Jerry Radich,David M. Ross,M.T. Gómez Casares,Andrzej Hellmann,Jesper Stentoft,Eibhlin Conneally,Valentín García Gutiérrez,Norbert Gattermann,Wiesław Wiktor Jędrzejczak,P. le Coutre,Bruno Martino,Susanne Saussele,Hans D. Menssen,Weiping Deng,Nancy Krunic,Véronique Bédoucha,G. Saglio

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

2017

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

Keywords:

Cancer research
Nilotinib
Myeloid leukemia
Biology
international scale
Major Molecular Response
Clinical endpoint
Internal medicine
Confidence interval
Oncology
Molecular Response
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

167

Citations